While Phase II-III studies include small datasets, comprising several hundred to several thousand patients, they provide the data necessary for drug approvals. The FDA approval of a drug is contingent on the drug company designing and implementing a post-marketing, or Phase IV study, designed to obtain additional data in a larger, real-world patient population. Join Dr. Keith Coffee as he explores how and why practicing physicians agree to participate in Phase IV studies. He will also address the common concerns many physicians raise regarding time spent and reimbursement for participating in these studies.
Is Marijuana a Replacement for Opioids?
Advocacy Groups in Patient-Focused Drug Development
Real World Solutions
PRA Health Sciences’ Real World Solutions team guides clients through the intricacies of real world research throughout the development life cycle.…